サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：子宮筋腫治療薬の世界市場：産業分析、規模、シェア、成長、動向、予測（2023～2030年）
市場調査レポート
商品コード
1377903

子宮筋腫治療薬の世界市場：産業分析、規模、シェア、成長、動向、予測（2023～2030年）

Global Uterine Fibroid Treatment Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日: | 発行: Value Market Research | ページ情報: 英文 172 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
子宮筋腫治療薬の世界市場：産業分析、規模、シェア、成長、動向、予測（2023～2030年）
出版日: 2023年09月01日
発行: Value Market Research
ページ情報: 英文 172 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の子宮筋腫治療薬の市場規模は、2022年に22億9,000万米ドルとなり、2023～2030年にかけてCAGR 11.9%で成長し、2030年には約56億3,000万米ドルに達すると予測されています。

子宮筋腫治療薬は、子宮筋腫の症状を管理するために処方される薬であり、子宮筋腫は子宮壁に発生する増殖または腫瘍（非がん性）です。これらの薬剤は通常、手術が直ちに必要でない場合、または侵襲性の低いアプローチが望ましい場合に使用されます。これらは月経多量出血、骨盤痛、圧迫感を引き起こす可能性があり、これらの症状を緩和することがこれらの薬剤の目的です。

市場力学

子宮筋腫治療薬市場は、子宮筋腫の有病率と女性の健康への影響を反映するいくつかの要因によって牽引されています。子宮筋腫は一般的な婦人科疾患であり、関連症状を管理するための薬剤に対する一貫した需要につながっています。月経多量出血、骨盤痛、圧迫感は、患者を生活の質を高める薬物介入を求めるように駆り立てる一般的な症状です。手術に伴う潜在的なリスクや回復を避けるために、非手術的な治療オプションが多くの女性に好まれています。子宮筋腫治療薬は、より侵襲性の低い選択肢を提供します。さらに、子宮筋腫を持つ女性の中には、妊孕性を維持することを目的とする人もいるため、子宮温存薬は魅力的な選択肢となっています。薬剤開発の継続的な進歩と患者の意識の高まりが、利用可能な治療選択肢の拡大に寄与しています。臨床ガイドラインや、子宮筋腫の一般的な症状である出血を最小限に抑えたいという要望が、これらの薬剤の使用をさらに後押ししています。子宮筋腫治療薬は個別化医療の役割も担っており、個々の患者のニーズに対応したオーダーメイドの治療計画を可能にしています。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、子宮筋腫治療薬の世界市場における各セグメントを包括的に評価することもできます。子宮筋腫治療薬業界の成長と動向は、この研究に全体的なアプローチを提供します。

地域分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける子宮筋腫治療薬市場の現在および将来の需要を強調する地域展望をカバーしています。さらに、本レポートでは、著名な全地域における個々の用途セグメントの需要・推定・予測に焦点を当てています。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 子宮筋腫治療薬 - 産業分析

  • イントロダクション - 市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 子宮筋腫治療薬の世界市場分析：薬剤クラス別

  • 概要：薬剤クラス別
  • 実績データと予測データ
  • 分析：薬剤クラス別
  • Gonadotropin-Releasing Hormone (GnRH) Agonists
  • Gonadotropin-Releasing Hormone (GnRH) Antagonists
  • Progestin-Releasing Intrauterine Device (IUD) & Contraceptives
  • Non-Hormonal Medications
  • その他

第6章 子宮筋腫治療薬の世界市場分析：タイプ別

  • 概要：タイプ別
  • 実績データと予測データ
  • 分析：タイプ別
  • Subserosal Fibroids
  • Intramural Fibroids
  • Submucosal Fibroids
  • Pedunculated Fibroids

第7章 子宮筋腫治療薬の世界市場分析：エンドユーザー別

  • 概要：エンドユーザー別
  • 実績データと予測データ
  • 分析：エンドユーザー別
  • 病院薬局
  • 小売薬局
  • その他

第8章 子宮筋腫治療薬の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第9章 子宮筋腫治療薬企業の競合情勢

  • 子宮筋腫治療薬市場の競争
  • 提携・協力・合意
  • 合併・買収
  • 新製品発売
  • その他の開発

第10章 企業プロファイル

  • 企業シェア分析
  • 市場集中度
  • Myovant Sciences GmbH
  • Pfizer Inc.
  • Abbvie Inc.
  • Ferring B.V.
  • AstraZeneca
  • Bayer AG
  • Amring Pharmaceuticals Inc.
  • Watson Pharma Inc.
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Drug Class (USD MN)
  • Gonadotropin-Releasing Hormone (GnRH) Agonists Market Sales by Geography (USD MN)
  • Gonadotropin-Releasing Hormone (GnRH) Antagonists Market Sales by Geography (USD MN)
  • Progestin-Releasing Intrauterine Device (IUD) & Contraceptives Market Sales by Geography (USD MN)
  • Non-Hormonal Medications Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis Market by Type (USD MN)
  • Subserosal Fibroids Market Sales by Geography (USD MN)
  • Intramural Fibroids Market Sales by Geography (USD MN)
  • Submucosal Fibroids Market Sales by Geography (USD MN)
  • Pedunculated Fibroids Market Sales by Geography (USD MN)
  • Analysis by End-User (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Uterine Fibroid Treatment Drugs Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Uterine Fibroid Treatment Drugs Report
  • Market Research Process
  • Market Research Methodology
  • Global Uterine Fibroid Treatment Drugs Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Drug Class
  • Market Attractiveness Analysis by Type
  • Market Attractiveness Analysis by End-User
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Drug Class (USD MN)
  • Gonadotropin-Releasing Hormone (GnRH) Agonists Market Sales by Geography (USD MN)
  • Gonadotropin-Releasing Hormone (GnRH) Antagonists Market Sales by Geography (USD MN)
  • Progestin-Releasing Intrauterine Device (IUD) & Contraceptives Market Sales by Geography (USD MN)
  • Non-Hormonal Medications Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Type (USD MN)
  • Subserosal Fibroids Market Sales by Geography (USD MN)
  • Intramural Fibroids Market Sales by Geography (USD MN)
  • Submucosal Fibroids Market Sales by Geography (USD MN)
  • Pedunculated Fibroids Market Sales by Geography (USD MN)
  • Global Market Analysis by End-User (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112112210

The global demand for Uterine Fibroid Treatment Drugs Market is presumed to reach the market size of nearly USD 5.63 BN by 2030 from USD 2.29 BN in 2022 with a CAGR of 11.9% under the study period 2023 - 2030.

Uterine fibroid treatment drugs are medications prescribed to manage the symptoms of uterine fibroids, which are growths or tumors (non-cancerous) that develop in the wall of the uterus. These drugs are typically used when surgery is not immediately necessary or when a less invasive approach is preferred. These can cause heavy menstrual bleeding, pelvic pain, and pressure, and the goal of these medications is to alleviate these symptoms.

MARKET DYNAMICS:

The Uterine fibroid treatment drugs market is driven by several factors reflecting the prevalence and impact of uterine fibroids on women's health. Uterine fibroids are a common gynecological condition, leading to a consistent demand for medications to manage associated symptoms. Heavy menstrual bleeding, pelvic pain, and pressure are common symptoms that drive patients to seek pharmaceutical interventions enhancing their quality of life. Non-surgical treatment options are preferred by many women to avoid the potential risks and recovery associated with surgery. Uterine fibroid treatment drugs offer a less invasive alternative. Additionally, some women with fibroids aim to preserve fertility, making uterine-sparing medications an appealing choice. Ongoing advancements in drug development and increasing patient awareness contribute to the expanding range of available treatment options. Clinical guidelines and the desire to minimize blood loss, a common symptom of fibroids, further support the use of these medications. Uterine fibroid treatment drugs also play a role in personalized medicine, allowing tailored treatment plans to address individual patient needs.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of uterine fibroid treatment drugs. The growth and trends of uterine fibroid treatment drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the uterine fibroid treatment drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

  • Gonadotropin-Releasing Hormone (GnRH) Agonists
  • Gonadotropin-Releasing Hormone (GnRH) Antagonists
  • Progestin-Releasing Intrauterine Device (IUD) & Contraceptives
  • Non-Hormonal Medications
  • Others

By Type

  • Subserosal Fibroids
  • Intramural Fibroids
  • Submucosal Fibroids
  • Pedunculated Fibroids

By End-User

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Uterine Fibroid Treatment Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Uterine Fibroid Treatment Drugs market include Myovant Sciences GmbH, Pfizer Inc., Abbvie Inc, Ferring B.V., AstraZeneca, Bayer AG, Amring Pharmaceuticals Inc., Watson Pharma Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . UTERINE FIBROID TREATMENT DRUGS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class
    • 3.7.2 Market Attractiveness Analysis By Type
    • 3.7.3 Market Attractiveness Analysis By End-User
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET ANALYSIS BY DRUG CLASS

  • 5.1 Overview by Drug Class
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Drug Class
  • 5.4 Gonadotropin-Releasing Hormone (GnRH) Agonists Historic and Forecast Sales by Regions
  • 5.5 Gonadotropin-Releasing Hormone (GnRH) Antagonists Historic and Forecast Sales by Regions
  • 5.6 Progestin-Releasing Intrauterine Device (IUD) & Contraceptives Historic and Forecast Sales by Regions
  • 5.7 Non-Hormonal Medications Historic and Forecast Sales by Regions
  • 5.8 Others Historic and Forecast Sales by Regions

6 . GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET ANALYSIS BY TYPE

  • 6.1 Overview by Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Type
  • 6.4 Subserosal Fibroids Historic and Forecast Sales by Regions
  • 6.5 Intramural Fibroids Historic and Forecast Sales by Regions
  • 6.6 Submucosal Fibroids Historic and Forecast Sales by Regions
  • 6.7 Pedunculated Fibroids Historic and Forecast Sales by Regions

7 . GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET ANALYSIS BY END-USER

  • 7.1 Overview by End-User
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by End-User
  • 7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
  • 7.5 Retail Pharmacies Historic and Forecast Sales by Regions
  • 7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. South East Asia Sales Analysis
    • 8.5.10. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE UTERINE FIBROID TREATMENT DRUGS COMPANIES

  • 9.1. Uterine Fibroid Treatment Drugs Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF UTERINE FIBROID TREATMENT DRUGS INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Myovant Sciences GmbH
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. Pfizer Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Abbvie Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Ferring B.V.
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. AstraZeneca
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Bayer AG
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. Amring Pharmaceuticals Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. Watson Pharma Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies